Zobrazeno 1 - 10
of 5 356
pro vyhledávání: '"MODIFYING ANTIRHEUMATIC DRUGS"'
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 3, Pp 285-298 (2024)
INTRODUCTION. Methotrexate (MTX) is the main disease-modifying antirheumatic drug (DMARD) and the gold standard for the safety and efficacy evaluation of biologicals and targeted small molecules. However, its narrow therapeutic range, interpatient va
Externí odkaz:
https://doaj.org/article/c90034379d744cd1a76784042e2f9437
Autor:
Alena S. Potapova, Andrey E. Karateev, Elena Yu. Polishchuk, Ekaterina S. Filatova, Vera N. Amirdzhanova, Aleksander M. Lila
Publikováno v:
Терапевтический архив, Vol 96, Iss 5, Pp 465-470 (2024)
Background. Clinical guidelines for the treatment of rheumatoid arthritis (RA) recommend reducing the use of glucocorticoids (GCs) due to the high risk of associated complications. Aim. To determine the frequency of GC cancellations and dose reduc
Externí odkaz:
https://doaj.org/article/844f2b6d3f7c44808ee780fb6a20ef87
Autor:
Kaustav Saha, Shatavisa Mukherjee
Publikováno v:
APIK Journal of Internal Medicine, Vol 12, Iss 4, Pp 241-243 (2024)
Sulfasalazine, a relatively well-tolerated, disease-modifying anti-rheumatoid drug has been reported to be associated with hepatic and cutaneous adverse events, in addition to its common adverse effect profile. The present case reports a reaction cas
Externí odkaz:
https://doaj.org/article/7a4332ca6bfa4c57b9b5aa90ba21a50c
Publikováno v:
Современная ревматология, Vol 18, Iss 4, Pp 93-98 (2024)
Therapy of systemic lupus erythematosus (SLE) remains a difficult task. Long-term use of glucocorticoids (GC) and cytostatic drugs significantly improves the prognosis of life, but at the same time contributes to the accumulation of irreversible dama
Externí odkaz:
https://doaj.org/article/14452f86e18f4de3b438137096ae6954
Autor:
N. V. Muravyova, B. S. Belov
Publikováno v:
Современная ревматология, Vol 18, Iss 4, Pp 115-120 (2024)
Patients with immune-mediated inflammatory rheumatic diseases (IIRD) are more likely to develop herpes zoster (HZ) than individuals in the general population. Live attenuated vaccines and inactivated recombinant vaccines with adjuvant are available t
Externí odkaz:
https://doaj.org/article/10edb354788743cdbfd6f9cbd64211e8
Autor:
N. V. Chichasova, A. M. Lila
Publikováno v:
Современная ревматология, Vol 18, Iss 4, Pp 106-114 (2024)
This review presents the latest data on the long-term use of the selective Janus kinase inhibitor (JAKi) baricitinib (BARI) in patients with rheumatoid arthritis (RA) in real-world clinical practice. The results of long-term use (up to 9.5 years) of
Externí odkaz:
https://doaj.org/article/634356a62607463e8e7b1472e041f6df
Publikováno v:
Современная ревматология, Vol 18, Iss 4, Pp 16-22 (2024)
Biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKis) do not always allow to achieve remission and low inflammatory activity in rheumatoid arthritis (RA), necessitating switching of therapy. Objective: to evalua
Externí odkaz:
https://doaj.org/article/c4dead8170214e6881b276a6bebefcf5
Autor:
R. M. Balabanova, L. N. Denisov
Publikováno v:
Современная ревматология, Vol 18, Iss 4, Pp 89-92 (2024)
The article discusses the pathogenesis and clinical manifestations of cutaneous vasculitis in rheumatoid arthritis (RA) and the role of autoimmune disturbances in the development of micro- and macrovascular thrombosis of the venous and arterial vesse
Externí odkaz:
https://doaj.org/article/cd3bbc16146c43438746e5c1daf3cc02
Autor:
M. I. Kaleda, I. P. Nikishina
Publikováno v:
Современная ревматология, Vol 18, Iss 4, Pp 99-105 (2024)
The treatment of juvenile-onset systemic lupus erythematosus (jSLE) is a complex task in view of the diversity of clinical manifestations and the course of the disease as well as the high risk of organ damage. The need to create separate therapeutic
Externí odkaz:
https://doaj.org/article/e253ceec35e44e31aa3824557ac8b96a
Autor:
Grace C. Wright, Eduardo Mysler, Kenneth Kwok, Mary Jane Cadatal, Rebecca Germino, Arne Yndestad, Cassandra D. Kinch, Alexis Ogdie
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1135-1164 (2024)
Abstract Introduction Racial disparities in disease activity, clinical outcomes, and treatment survival persist despite advancements in rheumatoid arthritis (RA) therapies and clinical management. In this post hoc analysis of pooled data from the tof
Externí odkaz:
https://doaj.org/article/7fc4cc04798247339219428e07071d32